Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (101-110 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology (Oxford, England)|September 9, 2021
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled studyVictoria P Werth, Roy Fleischmann, Michael Robern, et al.
Seminars in Arthritis and Rheumatism|May 24, 2012
Proceedings of the 2012 Rheumatology Winter Clinical SymposiaArthur Kavanaugh, George Martin, John J Cush, et al.
Current Medical Research and Opinion|July 23, 2014
Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch studyRoy Fleischmann, John A Goldman, Marjatta Leirisalo-Repo, et al.
Nature Reviews. Rheumatology|February 1, 2024
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianZoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, et al.
RMD Open|November 2, 2019
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trialVibeke Strand, Eduardo Mysler, Robert J Moots, et al.
RMD Open|October 19, 2016
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trialVibeke Strand, Eun Bong Lee, Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|November 18, 2017
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritisArthur Kavanaugh, Ronald F van Vollenhoven, Roy Fleischmann, et al.
International Journal of Rheumatic Diseases|July 26, 2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesRoy Fleischmann, Joel Kremer, Yoshiya Tanaka, et al.
Rheumatology (Oxford, England)|August 26, 2022
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPAREEduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|September 12, 2015
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialJeremy Sokolove, Michael Schiff, Roy Fleischmann, et al.
Pageof 19

Showing results (101-110 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology (Oxford, England)|September 9, 2021
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled studyVictoria P Werth, Roy Fleischmann, Michael Robern, et al.
Seminars in Arthritis and Rheumatism|May 24, 2012
Proceedings of the 2012 Rheumatology Winter Clinical SymposiaArthur Kavanaugh, George Martin, John J Cush, et al.
Current Medical Research and Opinion|July 23, 2014
Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch studyRoy Fleischmann, John A Goldman, Marjatta Leirisalo-Repo, et al.
Nature Reviews. Rheumatology|February 1, 2024
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianZoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, et al.
RMD Open|November 2, 2019
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trialVibeke Strand, Eduardo Mysler, Robert J Moots, et al.
RMD Open|October 19, 2016
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trialVibeke Strand, Eun Bong Lee, Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|November 18, 2017
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritisArthur Kavanaugh, Ronald F van Vollenhoven, Roy Fleischmann, et al.
International Journal of Rheumatic Diseases|July 26, 2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesRoy Fleischmann, Joel Kremer, Yoshiya Tanaka, et al.
Rheumatology (Oxford, England)|August 26, 2022
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPAREEduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|September 12, 2015
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trialJeremy Sokolove, Michael Schiff, Roy Fleischmann, et al.
Pageof 19